UN Weather Body: Ozone Layer on Road to Recovery Despite Volcano Eruption

FILE PHOTO: The eruption of an underwater volcano off Tonga, is seen in an image from the NOAA GOES-West satellite taken at 05:00 GMT January 15, 2022. CIRA/NOAA/Handout via REUTERS
FILE PHOTO: The eruption of an underwater volcano off Tonga, is seen in an image from the NOAA GOES-West satellite taken at 05:00 GMT January 15, 2022. CIRA/NOAA/Handout via REUTERS
TT

UN Weather Body: Ozone Layer on Road to Recovery Despite Volcano Eruption

FILE PHOTO: The eruption of an underwater volcano off Tonga, is seen in an image from the NOAA GOES-West satellite taken at 05:00 GMT January 15, 2022. CIRA/NOAA/Handout via REUTERS
FILE PHOTO: The eruption of an underwater volcano off Tonga, is seen in an image from the NOAA GOES-West satellite taken at 05:00 GMT January 15, 2022. CIRA/NOAA/Handout via REUTERS

The world's ozone layer is on "the road to long-term recovery" despite a destructive volcanic eruption in the South Pacific, the World Meteorological Organization said on Tuesday, after efforts to phase out ozone-depleting chemicals.
On current trends, the ozone layer is on track to recover to 1980 levels by around 2066 over the Antarctic, 2045 over the Arctic and 2040 for the rest of the world, the United Nations agency said.
Though the volcanic eruption near Tonga in early 2022 led to a short period of accelerated depletion of ozone above Antarctica last year, driven by higher levels of atmospheric water vapor, overall losses were limited, it said in its annual ozone bulletin.
The ozone layer protects the earth from the sun's ultraviolet radiation, which is linked to skin cancer and other health risks.
The Montreal Protocol, which came into effect in 1989, agreed to phase out chlorofluorocarbons and other ozone-depleting substances, and its success "stands out as a powerful symbol of hope" at a time when multilateral cooperation has come under strain, Reuters quoted UN Secretary-General Antonio Guterres as saying in a statement.
CFCs have been largely replaced by hydrofluorocarbons, which do not cause ozone depletion but are a powerful climate-warming greenhouse gas.
Countries are now implementing the 2016 Kigali amendment to Montreal, which will phase down HFC production, and could avoid around 0.5 degrees Celsius of warming by 2100.
China remains the world's biggest HFC producer, with current capacity the equivalent of nearly 2 billion metric tons of carbon dioxide. About a quarter is exported.
China's environment ministry said on Monday it would soon publish a plan to better control HFC production. As a developing country, it is obliged to cut HFC consumption by 85% from 2013 to 2045.
China is cutting manufacturing quotas and cracking down on illegal production, but it warned this year it still "faces huge challenges" in phasing down HFCs, which are used by a wide range of different industries, many of which have struggled to find substitute products.



Weight-Loss Drugs May Lower Cancer Risk in People with Diabetes, a Study Suggests 

A box of Ozempic made by Novo Nordisk is seen at a pharmacy in London, Britain March 8, 2024. (Reuters) 
A box of Ozempic made by Novo Nordisk is seen at a pharmacy in London, Britain March 8, 2024. (Reuters) 
TT

Weight-Loss Drugs May Lower Cancer Risk in People with Diabetes, a Study Suggests 

A box of Ozempic made by Novo Nordisk is seen at a pharmacy in London, Britain March 8, 2024. (Reuters) 
A box of Ozempic made by Novo Nordisk is seen at a pharmacy in London, Britain March 8, 2024. (Reuters) 

Excess body weight can raise the risk of certain cancers, leading researchers to wonder whether blockbuster drugs like Wegovy, Ozempic and Zepbound could play a role in cancer prevention.

Now, a study of 170,000 patient records suggests there's a slightly lower risk of obesity-related cancers in US adults with diabetes who took these popular medications compared to those who took another class of diabetes drug not associated with weight loss.

This type of study can't prove cause and effect, but the findings hint at a connection worth exploring. More than a dozen cancers are associated with obesity.

“This is a call to scientists and clinical investigators to do more work in this area to really prove or disprove this,” said Dr. Ernest Hawk of MD Anderson Cancer Center in Houston, who was not involved in the study.

The findings were released Thursday by the American Society of Clinical Oncology and will be discussed at its annual meeting in Chicago. The study, funded by the National Institutes of Health, was led by Lucas Mavromatis, a medical student at New York University’s Grossman School of Medicine.

“Chronic disease and chronic disease prevention are some of my passions,” said Mavromatis, a former research fellow with an NIH training program.

GLP-1 receptor agonists are injections used to treat diabetes, and some are also approved to treat obesity. They work by mimicking hormones in the gut and the brain to regulate appetite and feelings of fullness. They don't work for everyone and can produce side effects that include nausea and stomach pain.

In the study, researchers analyzed data from 43 US health systems to compare two groups: people with obesity and diabetes who took GLP-1 drugs and other people with the same conditions who took diabetes drugs like sitagliptin. The two groups were equal in size and matched for other characteristics.

After four years, those who took GLP-1 drugs had a 7% lower risk of developing an obesity-related cancer and an 8% lower risk of death from any cause compared to those who took the other type of diabetes drug. There were 2,501 new cases of obesity-related cancer in the GLP-1 group compared to 2,671 cases in the other group.

The effect was evident in women, but not statistically significant in men. The study couldn't explain that difference, but Mavromatis noted that differences in blood drug concentration, weight loss, metabolism or hormones could be at play.